• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过计算模拟和定向进化方法的结合,提高 VEGFR2 结合亲和体分子的热稳定性和改善其生物分布。

Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches.

机构信息

Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

出版信息

Sci Rep. 2020 Oct 23;10(1):18148. doi: 10.1038/s41598-020-74560-5.

DOI:10.1038/s41598-020-74560-5
PMID:33097752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7585445/
Abstract

The family of vascular endothelial growth factor (VEGF) ligands and their interactions with VEGF receptors (VEGFRs) play important roles in both pathological and physiological angiogenesis. Hence, agonistic and antagonistic ligands targeting this signaling pathway have potential for both studies on fundamental biology and for development of therapies and diagnostics. Here, we engineer VEGFR2-binding affibody molecules for increased thermostability, refolding and improved biodistribution. We designed libraries based on the original monomeric binders with the intention of reducing hydrophobicity, while retaining high affinity for VEGFR2. Libraries were displayed on bacteria and binders were isolated by fluorescence-activated cell sorting (FACS). In parallel, we used an automated sequence- and structure-based in silico algorithm to identify potentially stabilizing mutations. Monomeric variants isolated from the screening and the in silico approach, respectively, were characterized by circular dichroism spectroscopy and biosensor assays. The most promising mutations were combined into new monomeric constructs which were finally fused into a dimeric construct, resulting in a 15 °C increase in melting temperature, complete refolding capability after heat-induced denaturation, retained low picomolar affinity and improved biodistribution profile in an in vivo mouse model. These VEGFR2-binding affibody molecules show promise as candidates for further in vivo studies to assess their suitability as molecular imaging and therapeutic agents.

摘要

血管内皮生长因子(VEGF)配体家族及其与 VEGF 受体(VEGFR)的相互作用在病理性和生理性血管生成中起着重要作用。因此,针对该信号通路的激动剂和拮抗剂配体具有研究基础生物学和开发治疗方法和诊断方法的潜力。在这里,我们设计了具有更高热稳定性、重折叠能力和改善生物分布的 VEGFR2 结合亲和体分子。我们基于原始的单体结合物设计了文库,旨在降低疏水性,同时保留对 VEGFR2 的高亲和力。文库在细菌上展示,并用荧光激活细胞分选(FACS)分离结合物。同时,我们使用基于序列和结构的自动化计算算法来识别潜在的稳定化突变。从筛选和计算方法中分别分离出的单体变体,通过圆二色性光谱和生物传感器分析进行了表征。最有前途的突变被组合成新的单体构建体,最终融合成二聚体构建体,导致熔点提高 15°C,热诱导变性后完全重折叠能力,保留低皮摩尔亲和力,并改善体内小鼠模型中的生物分布特征。这些 VEGFR2 结合亲和体分子有望成为进一步体内研究的候选物,以评估它们作为分子成像和治疗剂的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/c901ff837186/41598_2020_74560_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/e348e8b9e000/41598_2020_74560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/0d9a973bef4b/41598_2020_74560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/a2cdd226e100/41598_2020_74560_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/0afb0e6cf7e9/41598_2020_74560_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/12cb73a86c44/41598_2020_74560_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/c901ff837186/41598_2020_74560_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/e348e8b9e000/41598_2020_74560_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/0d9a973bef4b/41598_2020_74560_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/a2cdd226e100/41598_2020_74560_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/0afb0e6cf7e9/41598_2020_74560_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/12cb73a86c44/41598_2020_74560_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3475/7585445/c901ff837186/41598_2020_74560_Fig6_HTML.jpg

相似文献

1
Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches.通过计算模拟和定向进化方法的结合,提高 VEGFR2 结合亲和体分子的热稳定性和改善其生物分布。
Sci Rep. 2020 Oct 23;10(1):18148. doi: 10.1038/s41598-020-74560-5.
2
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.使用双表位亲和体分子同时靶向血管内皮生长因子受体2(VEGFR2)上的两个配体结合位点可显著提高亲和力。
Sci Rep. 2014 Dec 17;4:7518. doi: 10.1038/srep07518.
3
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.利用通过位置定向易错 PCR 样多样化工程设计成低皮摩尔亲和力的亲和体分子抑制 HER3 介导的肿瘤细胞生长。
PLoS One. 2013 May 10;8(5):e62791. doi: 10.1371/journal.pone.0062791. Print 2013.
4
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.工程化设计的拮抗 VEGF 变体,可同时结合并抑制 VEGFR2 和 alphavbeta3 整合素。
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14067-72. doi: 10.1073/pnas.1016635108. Epub 2011 Aug 8.
5
Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.监测抗 hRaf-1 亲和体分子的整个基因体外进化以提高结合亲和力。
N Biotechnol. 2012 Jun 15;29(5):534-42. doi: 10.1016/j.nbt.2011.10.008. Epub 2011 Oct 19.
6
VEGFR2-Specific Ligands Based on Affibody Molecules Demonstrate Agonistic Effects when Tetrameric in the Soluble Form or Immobilized via Spider Silk.基于亲和体分子的VEGFR2特异性配体在以可溶性形式四聚化或通过蜘蛛丝固定时表现出激动作用。
ACS Biomater Sci Eng. 2019 Dec 9;5(12):6474-6484. doi: 10.1021/acsbiomaterials.9b00994. Epub 2019 Nov 13.
7
Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast.通过对展示在酵母上的文库施加强烈热休克来定向进化稳定的IgG1-Fc支架。
Biochim Biophys Acta. 2012 Apr;1824(4):542-9. doi: 10.1016/j.bbapap.2012.01.006. Epub 2012 Jan 20.
8
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.DOTA 螯合剂位置对 (111)In 标记的合成抗 HER2 亲和体分子的生物分布和靶向特性的影响。
Bioconjug Chem. 2012 Aug 15;23(8):1661-70. doi: 10.1021/bc3002369. Epub 2012 Jul 17.
9
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.通过体外定向蛋白质进化产生的人源和鼠源血管内皮生长因子受体2拮抗剂。
Chem Biol. 2006 May;13(5):549-56. doi: 10.1016/j.chembiol.2005.12.009.
10
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.基于分子动力学的深入洞察、结合自由能计算和药效团虚拟筛选以鉴定潜在的血管内皮生长因子受体2(VEGFR2)抑制剂
J Recept Signal Transduct Res. 2019 Oct-Dec;39(5-6):415-433. doi: 10.1080/10799893.2019.1690509. Epub 2019 Nov 22.

引用本文的文献

1
Moderate-Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein-2.中等亲和力的 Affibodies 可调节骨形态发生蛋白-2 的递送和生物活性。
Adv Healthc Mater. 2023 Oct;12(26):e2300793. doi: 10.1002/adhm.202300793. Epub 2023 Jul 9.
2
Non-invasive molecular imaging of kidney diseases.肾脏疾病的无创分子影像学。
Nat Rev Nephrol. 2021 Oct;17(10):688-703. doi: 10.1038/s41581-021-00440-4. Epub 2021 Jun 29.

本文引用的文献

1
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.分子设计对ABD融合的单价和双价抗HER3亲合体治疗构建体靶向特性的影响
Cells. 2018 Oct 11;7(10):164. doi: 10.3390/cells7100164.
2
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.使用双价靶向亲和体结合物对胶质瘤血管中的 VEGFR2 进行放射性核素成像:在小鼠模型中的初步验证。
Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.
3
Principles of Protein Stability and Their Application in Computational Design.
蛋白质稳定性原理及其在计算设计中的应用。
Annu Rev Biochem. 2018 Jun 20;87:105-129. doi: 10.1146/annurev-biochem-062917-012102. Epub 2018 Jan 26.
4
Staphylococcus carnosus: from starter culture to protein engineering platform.肉葡萄球菌:从起始培养物到蛋白质工程平台。
Appl Microbiol Biotechnol. 2017 Dec;101(23-24):8293-8307. doi: 10.1007/s00253-017-8528-6. Epub 2017 Oct 2.
5
Affibody Molecules in Biotechnological and Medical Applications.亲和体分子在生物技术和医疗应用中的应用。
Trends Biotechnol. 2017 Aug;35(8):691-712. doi: 10.1016/j.tibtech.2017.04.007. Epub 2017 May 14.
6
Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability.基于结构和序列的蛋白质自动化设计,以实现高效细菌表达和稳定性
Mol Cell. 2016 Jul 21;63(2):337-346. doi: 10.1016/j.molcel.2016.06.012. Epub 2016 Jul 14.
7
Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.用于中和血管内皮生长因子(VEGF)信号传导的新型亲和结合剂。
Cell Mol Life Sci. 2016 Apr;73(8):1671-83. doi: 10.1007/s00018-015-2088-7. Epub 2015 Nov 9.
8
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.使用双表位亲和体分子同时靶向血管内皮生长因子受体2(VEGFR2)上的两个配体结合位点可显著提高亲和力。
Sci Rep. 2014 Dec 17;4:7518. doi: 10.1038/srep07518.
9
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.雷莫芦单抗单药治疗既往治疗的晚期胃或胃食管结合部腺癌(REGARD):一项国际、随机、多中心、安慰剂对照、3 期临床试验。
Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.
10
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.利用通过位置定向易错 PCR 样多样化工程设计成低皮摩尔亲和力的亲和体分子抑制 HER3 介导的肿瘤细胞生长。
PLoS One. 2013 May 10;8(5):e62791. doi: 10.1371/journal.pone.0062791. Print 2013.